<SEC-DOCUMENT>0001950047-25-010708.txt : 20251229
<SEC-HEADER>0001950047-25-010708.hdr.sgml : 20251229
<ACCEPTANCE-DATETIME>20251229090800
ACCESSION NUMBER:		0001950047-25-010708
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251229
DATE AS OF CHANGE:		20251229

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cogent Biosciences, Inc.
		CENTRAL INDEX KEY:			0001622229
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				465308248
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38443
		FILM NUMBER:		251603887

	BUSINESS ADDRESS:	
		STREET 1:		275 WYMAN STREET
		STREET 2:		3RD FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-945-5576

	MAIL ADDRESS:	
		STREET 1:		275 WYMAN STREET
		STREET 2:		3RD FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Unum Therapeutics Inc.
		DATE OF NAME CHANGE:	20180402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Unum Therapeutics, Inc.
		DATE OF NAME CHANGE:	20141014

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Robinson John Edward
		CENTRAL INDEX KEY:			0001856514
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O COGENT BIOSCIENCES, INC.
		STREET 2:		200 CAMBRIDGE PARK DRIVE, SUITE 2500
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:ns2="http://www.sec.gov/edgar/common">
    <headerData>
        <submissionType>144</submissionType>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0001856514</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>



        </filerInfo>
    </headerData>
    <formData>
        <issuerInfo>
            <issuerCik>0001622229</issuerCik>
            <issuerName>COGENT BIOSCIENCES, INC.</issuerName>
            <secFileNumber>001-38443</secFileNumber>
            <issuerAddress>
                <ns2:street1>275 Wyman Street, 3rd Floor</ns2:street1>
                <ns2:city>Waltham</ns2:city>
                <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                <ns2:zipCode>02451</ns2:zipCode>
            </issuerAddress>
            <issuerContactPhone>(617) 945-5576</issuerContactPhone>
            <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>JOHN ROBINSON</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <relationshipsToIssuer>
                <relationshipToIssuer>Officer</relationshipToIssuer>
            </relationshipsToIssuer>
        </issuerInfo>
        <securitiesInformation>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <brokerOrMarketmakerDetails>
                <name>Morgan Stanley Smith Barney LLC Executive Financial Services</name>
                <address>
                    <ns2:street1>1 New York Plaza</ns2:street1>
                    <ns2:street2>8th Floor</ns2:street2>
                    <ns2:city>New York</ns2:city>
                    <ns2:stateOrCountry>NY</ns2:stateOrCountry>
                    <ns2:zipCode>10004</ns2:zipCode>
                </address>
            </brokerOrMarketmakerDetails>
            <noOfUnitsSold>90000</noOfUnitsSold>
            <aggregateMarketValue>3486276.00</aggregateMarketValue>
            <noOfUnitsOutstanding>142376529</noOfUnitsOutstanding>
            <approxSaleDate>12/26/2025</approxSaleDate>
            <securitiesExchangeName>NASDAQ</securitiesExchangeName>
        </securitiesInformation>
        <securitiesToBeSold>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <acquiredDate>12/17/2025</acquiredDate>
            <natureOfAcquisitionTransaction>Performance Shares</natureOfAcquisitionTransaction>
            <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
            <isGiftTransaction>N</isGiftTransaction>
            <amountOfSecuritiesAcquired>45000</amountOfSecuritiesAcquired>
            <paymentDate>12/17/2025</paymentDate>
            <natureOfPayment>Not Applicable</natureOfPayment>
        </securitiesToBeSold>
        <securitiesToBeSold>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <acquiredDate>12/17/2025</acquiredDate>
            <natureOfAcquisitionTransaction>Performance Shares</natureOfAcquisitionTransaction>
            <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
            <isGiftTransaction>N</isGiftTransaction>
            <amountOfSecuritiesAcquired>45000</amountOfSecuritiesAcquired>
            <paymentDate>12/17/2025</paymentDate>
            <natureOfPayment>Not Applicable</natureOfPayment>
        </securitiesToBeSold>
        <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <remarks>Sales that were executed on December 26, 2025 are being reported on this Form 144 filed on December 29, 2025 given December 26, 2025 was treated as federal holidays for EDGAR filing purposes.</remarks>
        <noticeSignature>
            <noticeDate>12/26/2025</noticeDate>
            <planAdoptionDates/>
            <signature>/s/ John Edward Robinson</signature>
        </noticeSignature>
    </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
